Table of Contents

March 2, 2004; 140 (5)

Articles

  • Effect of Antibacterial Home Cleaning and Handwashing Products on Infectious Disease Symptoms: A Randomized, Double-Blind Trial

    • Elaine L. Larson,
    • Susan X. Lin,
    • Cabilia Gomez-Pichardo,
    • and Phyllis Della-Latta
    Ann Intern Med March 2, 2004 140:321-329

    Antibacterial products for general cleaning, laundry, and handwashing did not reduce the frequency of symptoms of viral infectious disease in households of essentially healthy persons. This result does not preclude the possibility that these home products reduce bacterial disease symptoms.

  • Factor V Leiden and the Risk for Venous Thromboembolism in the Adult Danish Population

    • Klaus Juul,
    • Anne Tybjærg-Hansen,
    • Peter Schnohr,
    • and Børge G. Nordestgaard
    Ann Intern Med March 2, 2004 140:330-337

    In the adult Danish population, heterozygotes for the factor V Leiden mutation had a hazard ratio of 3 for venous thromboembolism relative to noncarriers of the mutation. For homozygotes, the hazard ratio was 18. When smoking, obesity, and old age were all present, the absolute 10-year thromboembolic risk was 10% in heterozygotes and 51% in homozygotes.

  • Excess Body Weight Is Not Independently Associated with Outcome in Mechanically Ventilated Patients with Acute Lung Injury

    • James M. O'Brien, Jr.,
    • Carolyn H. Welsh,
    • Ronald H. Fish,
    • Marek Ancukiewicz,
    • Andrew M. Kramer,
    • and for the National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network*
    Ann Intern Med March 2, 2004 140:338-345

    Mechanically ventilated patients with acute lung injury have the same risk-adjusted outcomes whether they are obese or overweight or have normal body mass index. O'Brien and colleagues' findings suggest that normal weight, overweight, or obese patients benefit equally from lower tidal volume ventilation for acute lung injury.

  • Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C: A Randomized Study of Treatment Duration and Ribavirin Dose

    • Stephanos J. Hadziyannis,
    • Hoel Sette, Jr.,
    • Timothy R. Morgan,
    • Vijayan Balan,
    • Moises Diago,
    • Patrick Marcellin,
    • Giuliano Ramadori,
    • Henry Bodenheimer, Jr.,
    • David Bernstein,
    • Mario Rizzetto,
    • Stefan Zeuzem,
    • Paul J. Pockros,
    • Amy Lin,
    • Andrew M. Ackrill,
    • and for the PEGASYS International Study Group*
    Ann Intern Med March 2, 2004 140:346-355

    The researchers assessed the efficacy and safety of 24 or 48 weeks of treatment for chronic hepatitis C virus (HCV) infection with peginterferon-α2a plus a low or standard dose of ribavirin. The results suggest individualized treatment according to genotype. Patients with HCV genotype 1 require treatment for 48 weeks and a standard dose of ribavirin; for those with genotypes 2 and 3, 24 weeks of treatment with peginterferon-α2a and a low dose of ribavirin is sufficient.

Improving Patient Care

  • Communicating about Health Care: Observations from Persons Who Are Deaf or Hard of Hearing

    • Lisa I. Iezzoni,
    • Bonnie L. O'Day,
    • Mary Killeen,
    • and Heather Harker
    Ann Intern Med March 2, 2004 140:356-362

    Persons who are deaf or hard of hearing face considerable barriers to communicating with physicians. As the population ages, physicians will encounter many more persons with hearing limitations. Ensuring effective communication is essential to safe, timely, efficient, and patient-centered care. The authors offer practical advice that we all need to hear.

Review

  • Heterogeneous Virologic Response Rates to Interferon-Based Therapy in Patients with Chronic Hepatitis C: Who Responds Less Well?

    • Stefan Zeuzem
    Ann Intern Med March 2, 2004 140:370-381

    This article reviews the data on interferon-based therapies among patients with hepatitis C whose clinical findings mean that they are relatively unlikely to have a sustained virologic response. It also discusses the potential of the new pegylated interferons.

Clinical Guidelines

  • Screening for Family and Intimate Partner Violence: Recommendation Statement

    • U.S. Preventive Services Task Force*
    Ann Intern Med March 2, 2004 140:382-386

    The U.S. Preventive Services Task Force found insufficient evidence to recommend for or against routine screening of parents or guardians for the physical abuse or neglect of children, of women for intimate partner violence, or of older adults or their caregivers for elder abuse.

  • Screening Women and Elderly Adults for Family and Intimate Partner Violence: A Review of the Evidence for the U.S. Preventive Services Task Force

    • Heidi D. Nelson,
    • Peggy Nygren,
    • Yasmin McInerney,
    • and Jonathan Klein
    Ann Intern Med March 2, 2004 140:387-396

    This review provides the evidence to support the U.S. Preventive Services Task Force's position on screening for family and intimate partner violence.

Editorials

  • Beyond Semmelweis: Moving Infection Control into the Community

    • J. Todd Weber and
    • James M. Hughes
    Ann Intern Med March 2, 2004 140:397-398

    In this issue, Larson and colleagues found no difference in rates of infectious disease symptoms among families who used handwashing and household-cleaning products with and without antibacterial ingredients. Their trial shows that we can hold nonmedical products that claim to have health benefits to the same standard of evidence as new drugs, as we strive to provide the evidence base for public health recommendations.

  • Screening for Family Violence: What's an Evidence-Based Doctor To Do?

    • Mark S. Lachs
    Ann Intern Med March 2, 2004 140:399-400

    In this issue, Nelson and colleagues found essentially no studies of reasonable quality supporting specific effective intervention for family violence. In light of the evidence, why should clinicians screen for a disease for which there are no proven effective interventions? Because for some conditions that clinicians regularly encounter, robotic devotion to evidence-based medicine places us at risk of dehumanizing certain aspects of doctoring.

Letters

  • Metformin Hepatotoxicity

    • M. Deutsch,
    • D. Kountouras,
    • and S. P. Dourakis
    Ann Intern Med March 2, 2004 140:W-25

  • Management of the Clinically Inapparent Adrenal Mass

    • Paul M. Copeland
    Ann Intern Med March 2, 2004 140:401

  • Management of the Clinically Inapparent Adrenal Mass

    • Glenn D. Braunstein and
    • for the National Institutes of Health State-of-the Science Adrenal Incidentaloma Panel
    Ann Intern Med March 2, 2004 140:401-402

  • Postmenopausal Hormone Replacement Therapy and Cardiovascular Disease

    • Arnold B. Ritterband and
    • Israeli A. Jaffe
    Ann Intern Med March 2, 2004 140:402

  • Advance Directives, Due Process, and Medical Futility

    • Jeffrey T. Berger
    Ann Intern Med March 2, 2004 140:402-403

  • Advance Directives, Due Process, and Medical Futility

    • Thomas E. Finucane
    Ann Intern Med March 2, 2004 140:403

  • Advance Directives, Due Process, and Medical Futility

    • Anne L. Flamm and
    • Martin L. Smith
    Ann Intern Med March 2, 2004 140:403-404

  • Advance Directives, Due Process, and Medical Futility

    • Robert L. Fine and
    • Thomas Wm. Mayo
    Ann Intern Med March 2, 2004 140:404

  • Infliximab for Recurrent, Sight-Threatening Ocular Inflammation in Adamantiades–Behçet Disease

    • P. P. Sfikakis,
    • P. H. Kaklamanis,
    • A. Elezoglou,
    • N. Katsilambros,
    • P. G. Theodossiadis,
    • S. Papaefthimiou,
    • and N. Markomichelakis
    Ann Intern Med March 2, 2004 140:404-406

  • Acute Renal Failure Associated with Legionellosis

    • Ursula C. Brewster
    Ann Intern Med March 2, 2004 140:406-407

  • Correction: The Future of Primary Care

    Ann Intern Med March 2, 2004 140:407

Medical Writings: Book Notes

  • Diagnosis and Management of Adult Congenital Heart Disease

    • Gregory A. Crooke and
    • Thierry H. Le Jemtel
    Ann Intern Med March 2, 2004 140:408

  • Drugs for Pregnant and Lactating Women

    • David M. Stamilio
    Ann Intern Med March 2, 2004 140:408

Book Listings

  • Book Listings

    Ann Intern Med March 2, 2004 140:0

Medical Notices

  • Medical Notices

    Ann Intern Med March 2, 2004 140:0

Summaries for Patients

  • Use of Household Cleaning Products with Antibacterial Ingredients Did Not Reduce Symptoms of Infection

    Ann Intern Med March 2, 2004 140:I-30

  • Blood Clots in People with Factor V Leiden Mutation

    Ann Intern Med March 2, 2004 140:I-50

  • Excess Body Weight and Outcomes of Acute Lung Injury Requiring Mechanical Ventilation

    Ann Intern Med March 2, 2004 140:I-56

  • Duration and Dose of Antiviral Treatment for Chronic Hepatitis C

    Ann Intern Med March 2, 2004 140:I-67

  • Communication and Perceptions of Health Care: Observations and Suggestions from Persons Who Are Deaf or Hard of Hearing

    Ann Intern Med March 2, 2004 140:I-68

  • Screening for Family Violence: Recommendations from the U.S. Preventive Services Task Force

    Ann Intern Med March 2, 2004 140:I-70

Updates from the Annual Session

  • Update in Hospital Medicine

    • Andrew D. Auerbach and
    • Jennifer Kleinbart
    Ann Intern Med March 2, 2004 140:363-369

    The articles discussed in this Update cover topics important for general internists with active inpatient practices. These original research papers published in 2002 gave new insights into common inpatient diagnoses and frequent challenges for inpatient physicians.

« Previous | Next Issue »

This Issue

March 2, 2004; 140 (5)
  1. Articles
  2. Improving Patient Care
  3. Review
  4. Clinical Guidelines
  5. Editorials
  6. Letters
  7. Medical Writings: Book Notes
  8. Book Listings
  9. Medical Notices
  10. Summaries for Patients
  11. Updates from the Annual Session

Search in this issue:

Current Issue

  1. November 17, 2009, 151 (10)
  1. Alert me to current issues